A harmonized longitudinal biomarkers and cognition database for assessing the natural history of preclinical Alzheimer's disease from young adulthood and for designing prevention trials

the Dominantly Inherited Alzheimer Network

Research output: Contribution to journalArticle

Abstract

Introduction: Large longitudinal biomarkers database focusing on middle age is needed for Alzheimer's disease (AD) prevention. Methods: Data for cerebrospinal fluid analytes, molecular imaging of cerebral fibrillar β-amyloid with positron emission tomography, magnetic resonance imaging–based brain structures, and clinical/cognitive outcomes were harmonized across eight AD biomarker studies. Statistical power was estimated. Results: The harmonized database included 7779 participants with clinical/cognitive data: 3542 were 18∼65 years at the baseline, 5865 had longitudinal cognitive data for a median of 4.7 years, 2473 participated in the cerebrospinal fluid studies (906 had longitudinal data), 2496 participated in the magnetic resonance imaging studies (1283 had longitudinal data), and 1498 participated in the positron emission tomography amyloid studies (849 had longitudinal data). The database provides adequate power for detecting early biomarker changes, and demonstrates the feasibility of AD prevention trials on middle-aged individuals. Discussion: The harmonized database is an optimum resource to design AD prevention trials decades before symptomatic onset.

Original languageEnglish (US)
JournalAlzheimer's and Dementia
DOIs
StateAccepted/In press - Jan 1 2019

Fingerprint

Cognition
Alzheimer Disease
Biomarkers
Databases
Amyloid
Positron-Emission Tomography
Cerebrospinal Fluid
Molecular Imaging
Magnetic Resonance Spectroscopy
Magnetic Resonance Imaging
Brain

Keywords

  • Alzheimer disease
  • Amyloid imaging with positron emission tomography (PET) using the [C] benzothiazole tracer
  • Biomarkers
  • Cerebrospinal fluid (CSF)
  • Magnetic resonance imaging (MRI) volumetrics
  • Pittsburgh Compound-B (PIB)
  • Preclinical stages
  • Prevention trials

ASJC Scopus subject areas

  • Epidemiology
  • Health Policy
  • Developmental Neuroscience
  • Clinical Neurology
  • Geriatrics and Gerontology
  • Cellular and Molecular Neuroscience
  • Psychiatry and Mental health

Cite this

@article{a3d1c9303c394082911b258b7f6a3bc0,
title = "A harmonized longitudinal biomarkers and cognition database for assessing the natural history of preclinical Alzheimer's disease from young adulthood and for designing prevention trials",
abstract = "Introduction: Large longitudinal biomarkers database focusing on middle age is needed for Alzheimer's disease (AD) prevention. Methods: Data for cerebrospinal fluid analytes, molecular imaging of cerebral fibrillar β-amyloid with positron emission tomography, magnetic resonance imaging–based brain structures, and clinical/cognitive outcomes were harmonized across eight AD biomarker studies. Statistical power was estimated. Results: The harmonized database included 7779 participants with clinical/cognitive data: 3542 were 18∼65 years at the baseline, 5865 had longitudinal cognitive data for a median of 4.7 years, 2473 participated in the cerebrospinal fluid studies (906 had longitudinal data), 2496 participated in the magnetic resonance imaging studies (1283 had longitudinal data), and 1498 participated in the positron emission tomography amyloid studies (849 had longitudinal data). The database provides adequate power for detecting early biomarker changes, and demonstrates the feasibility of AD prevention trials on middle-aged individuals. Discussion: The harmonized database is an optimum resource to design AD prevention trials decades before symptomatic onset.",
keywords = "Alzheimer disease, Amyloid imaging with positron emission tomography (PET) using the [C] benzothiazole tracer, Biomarkers, Cerebrospinal fluid (CSF), Magnetic resonance imaging (MRI) volumetrics, Pittsburgh Compound-B (PIB), Preclinical stages, Prevention trials",
author = "{the Dominantly Inherited Alzheimer Network} and Chengjie Xiong and Jingqin Luo and Folasade Agboola and Yan Li and Marilyn Albert and Johnson, {Sterling C.} and Koscik, {Rebecca L.} and Masters, {Colin L.} and Anja Soldan and Villemagne, {Victor L.} and Li, {Qiao Xin} and McDade, {Eric M.} and Fagan, {Anne M.} and Parinaz Massoumzadeh and Tammie Benzinger and J. Hassenstab and Bateman, {Randall J.} and Morris, {John C.}",
year = "2019",
month = "1",
day = "1",
doi = "10.1016/j.jalz.2019.06.4955",
language = "English (US)",
journal = "Alzheimer's and Dementia",
issn = "1552-5260",
publisher = "Elsevier Inc.",

}

TY - JOUR

T1 - A harmonized longitudinal biomarkers and cognition database for assessing the natural history of preclinical Alzheimer's disease from young adulthood and for designing prevention trials

AU - the Dominantly Inherited Alzheimer Network

AU - Xiong, Chengjie

AU - Luo, Jingqin

AU - Agboola, Folasade

AU - Li, Yan

AU - Albert, Marilyn

AU - Johnson, Sterling C.

AU - Koscik, Rebecca L.

AU - Masters, Colin L.

AU - Soldan, Anja

AU - Villemagne, Victor L.

AU - Li, Qiao Xin

AU - McDade, Eric M.

AU - Fagan, Anne M.

AU - Massoumzadeh, Parinaz

AU - Benzinger, Tammie

AU - Hassenstab, J.

AU - Bateman, Randall J.

AU - Morris, John C.

PY - 2019/1/1

Y1 - 2019/1/1

N2 - Introduction: Large longitudinal biomarkers database focusing on middle age is needed for Alzheimer's disease (AD) prevention. Methods: Data for cerebrospinal fluid analytes, molecular imaging of cerebral fibrillar β-amyloid with positron emission tomography, magnetic resonance imaging–based brain structures, and clinical/cognitive outcomes were harmonized across eight AD biomarker studies. Statistical power was estimated. Results: The harmonized database included 7779 participants with clinical/cognitive data: 3542 were 18∼65 years at the baseline, 5865 had longitudinal cognitive data for a median of 4.7 years, 2473 participated in the cerebrospinal fluid studies (906 had longitudinal data), 2496 participated in the magnetic resonance imaging studies (1283 had longitudinal data), and 1498 participated in the positron emission tomography amyloid studies (849 had longitudinal data). The database provides adequate power for detecting early biomarker changes, and demonstrates the feasibility of AD prevention trials on middle-aged individuals. Discussion: The harmonized database is an optimum resource to design AD prevention trials decades before symptomatic onset.

AB - Introduction: Large longitudinal biomarkers database focusing on middle age is needed for Alzheimer's disease (AD) prevention. Methods: Data for cerebrospinal fluid analytes, molecular imaging of cerebral fibrillar β-amyloid with positron emission tomography, magnetic resonance imaging–based brain structures, and clinical/cognitive outcomes were harmonized across eight AD biomarker studies. Statistical power was estimated. Results: The harmonized database included 7779 participants with clinical/cognitive data: 3542 were 18∼65 years at the baseline, 5865 had longitudinal cognitive data for a median of 4.7 years, 2473 participated in the cerebrospinal fluid studies (906 had longitudinal data), 2496 participated in the magnetic resonance imaging studies (1283 had longitudinal data), and 1498 participated in the positron emission tomography amyloid studies (849 had longitudinal data). The database provides adequate power for detecting early biomarker changes, and demonstrates the feasibility of AD prevention trials on middle-aged individuals. Discussion: The harmonized database is an optimum resource to design AD prevention trials decades before symptomatic onset.

KW - Alzheimer disease

KW - Amyloid imaging with positron emission tomography (PET) using the [C] benzothiazole tracer

KW - Biomarkers

KW - Cerebrospinal fluid (CSF)

KW - Magnetic resonance imaging (MRI) volumetrics

KW - Pittsburgh Compound-B (PIB)

KW - Preclinical stages

KW - Prevention trials

UR - http://www.scopus.com/inward/record.url?scp=85071846017&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85071846017&partnerID=8YFLogxK

U2 - 10.1016/j.jalz.2019.06.4955

DO - 10.1016/j.jalz.2019.06.4955

M3 - Article

C2 - 31506247

AN - SCOPUS:85071846017

JO - Alzheimer's and Dementia

JF - Alzheimer's and Dementia

SN - 1552-5260

ER -